Amendments to the Specification

1. Please replace the paragraph on page 32, lines 6 to 8 with the following paragraph:

A yeast protein disulphide isomerase precursor, PDI1, can be found as Genbank accession no. CAA42373 or BAA00723. It has the following sequence of 522 amino acids (SEQ ID NO: 3):

2. Please replace the paragraph on page 32, lines 20 to 21 with the following paragraph:

An alternative PDI sequence can be found as Genbank accession no. CAA38402. It has the following sequence of 530 amino acids (SEQ ID NO: 4):

3. Please replace the paragraph on page 34, line 8 with the following paragraph:

One published protein sequence of SSA1 is as follows (SEQ ID NO: 5):

4. Please replace the paragraph on page 34, lines 22 to 24 with the following paragraph:

A published coding sequence for SSA1 is a follows, although it will be appreciated that the sequence can be modified by degenerate substitutions to obtain alternative nucleotide sequences which encode an identical protein product (SEQ ID NO: 6):

Synnestvedt & Lechner LLP In Re: Application of D. Sleep, et al

U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 3

5. Please replace the paragraph on page 37, line 26 with the following paragraph:

A published protein sequence for the protein pselp is a follows (SEQ ID NO: 7):

6. Please replace the paragraph on page 38, lines 14 to 16 with the following

paragraph:

A published nucleotide coding sequence of PSE1 is a follows, although it will be appreciated that

the sequence can be modified by degenerate substitutions to obtain alternative nucleotide

sequences which encode an identical protein product (SEQ ID NO: 8):

7. Please replace the paragraph on page 42, line 24 with the following paragraph:

One published sequence of Orm2p is as follows (SEQ ID NO: 9):

8. Please replace the paragraph on page 42, line 31 to page 43, line 2 with the

following paragraph:

The above protein is encoded in S. cerevisiae by the following coding nucleotide

sequence, although it will be appreciated that the sequence can be modified by degenerate

substitutions to obtain alternative nucleotide sequences which encode an identical protein

product (SEQ ID NO: 10):

Synnestvedt & Lechner LLP In Re: Application of D. Sleep, et al U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 4

9. Please replace the paragraph on page 66, lines 12 and 13 with the following Paragraph:

CF86 GGAGTGGTA CGTATTAATT AAGGCCGGCC AGGCCCGGGT ACGTACCAAT TGA (SEQ ID NO: 11) CF87 TCCTCACCAT GCATAATTAA TTCCGGCCGG TCCGGGCCCA TGCATGGTTA AC (SEQ ID NO: 12)

10. Please replace Table 1 on page 66 with the following table:

Primer	Description	Sequence
CF88	REP2 primer, 20mer	5'-ATCACGTAATACTTCTAGGG-3'
(SEQ ID NO: 13)		
CF98	REP2 primer, 20mer	5'-AGAGTGAGTTGGAAGGAAGG-3'
(SEQ ID NO: 14)		
CF99	REP2 primer, 20mer	5'-AGCTCGTAAGCGTCGTTACC-3'
(SEQ ID NO: 15)		
CF90	FLP primer, 20mer	5'-CTAGTTTCTCGGTACTATGC-3'
(SEQ ID NO: 16)		
CF91	FLP primer, 20mer	5'-GAGTTGACTAATGTTGTGGG-3'
(SEQ ID NO: 17)		

Attorney Docket No. P31,747 USA September 20, 2007

Page: 5

11. Please replace the table on page 67 with the following table:

Primer	Description	Sequence
CF100	FLP primer, 20mer	5'-AAAGCTTTGAAGAAAAATGC-3'
(SEQ ID NO: 18)		
CF101	FLP primer, 20mer	5'-GCAAGGGGTAGGATCGATCC-3'
(SEQ ID No: 19)		
CF123	pDB2783 MCS, 24mer	5'-ATTCGAGCTCGGTACCTACGTACT-3'
(SEQ ID NO: 20)		
CF126	pDB2783 MCS, 24mer	5'-CCCGGGCACGTGGGATCCTCTAGA-3'
(SEQ ID No: 21)		
M13-Forward	pDB2783 MCS, 17mer	5'-GTAAAACGACGGCCAGT-3'
(SEQ ID NO: 22)		
M13-Reverse	pDB2783 MCS, 16mer	5'-AACAGCTATGACCATG-3'
(SEQ ID NO: 23)		
CF129	Inverted repeat primer,	5'-GTGTTTATGCTTAAATGCG-3'
(SEQ ID NO: 24)	19mer	
CF130	REP2 primer, 20mer	5'-TCCTCTTGCATTTGTGTCTC-3'
(SEQ ID NO: 25)		
CF131	REP2 primer, 19mer	5'-ATCTTCCTATTATTATAGC-3'
(SEQ ID NO: 26)		

SYNNESTVEDT & LECHNER LLP

In Re: Application of D. Sleep, et al U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 6

12. Please replace the paragraph on page 68, lines 15 to 16 with the following paragraph::

CF104 Pi-GTATTAATTA AGGCCGGCCA GGCCCGGGTA C
CF105 CATAATTAAT TCCGGCCGGT CCGGGCCCAT G-Pi (SEQ ID NO: 28)

13. Please replace the paragraph on page 68, lines 35 and 36 with the following paragraph:

CF120 Pi-GTAATAATA CGTATTAATT AAGGCCGGCC AGGCCCGGGT ACGTAA (SEQ ID NO:29)
CF121 TCATTATTAT GCATAATTAA TTCCGGCCGG TCCGGGCCCA TGCAT-Pi (SEQ ID NO:30)

14. Please replace the paragraph on page 73, lines 8 and 9 with the following paragraph:

CF108 ATAATAATAC GTATTAATTA AGGCCGGCCA GGCCCGGGTA CGTA (SEQ ID NO: 31)
CF109 TATTATTATG CATAATTAAT TCCGGCCGGT CCGGGCCCAT GCAT (SEQ ID NO: 32)

15. Please replace the paragrpah on page 74, lines 10 and 11 with the following paragraph:

ACCATCACT GAGGGCCCTA AAGCG (SEQ ID NO: 33)
TGGTAGTGA CTCCCGGGAT (SEQ ID NO: 34)

16. Please replace the paragraph on page 74, lines 23 and 24 with the following paragraph:

CF116 Pi-CTTAAT AATACGTATT AATTAAGGCC GGCCAGGCCC GGGTACGTAG GGCC (SEQ ID NO: 35)
CF117 CCGGGAATTA TTATGCATAA TTAATTCCGG CCGGTCCGGG CCCATGCATC-Pi (SEQ ID NO: 36)

Synnestvedt & Lechner LLP In Re: Application of D. Sleep, et al U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 7

17. Please replace the paragraph on page 75, lines 8 and 9 with the following paragraph:

CF106 Pi-TAATAATACG TATTAATTAA GGCCGGCCAG GCCCGGGTAC GTA (SEQ ID NO: 37) ATTATTATGC ATAATTAATT CCGGCCGGTC CGGGCCCATG CAT-Pi (SEQ ID NO: 38)

18. Please replace the paragraph on page 76, lines 21 and 22 with the following paragraph:

CF118 Pi-GATCACTAATAATACGTATTAATTAAGGCCGGCCAGGCCCGGGTACGTA (SEQ ID NO: 39) CF119 GATTATTATGCATAATTAATTCCGGCCGGTCCGGGCCCATGCATCTAG-Pi (SEQ ID NO: 40)

19. Please replace the paragraph on page 77, lines 19 and 20 with the following paragraph:

CF114 Pi-AGTACTATAATACGTATTAATTAAGGCCGGCCAGGCCCGGGTACGTA (SEQ ID NO: 41) ATATTATGCATAATTAATTCCGGCCGGTCCGGGCCCATGCATTCATG-Pi (SEQ ID NO: 42) CF115

20. Pease replace the paragraph on page 82, lines 7 and 8 with the following Paragraph (underlining in sequences are in original):

CF127 5'-CGTAATACTTCTAGGGTATGATACGTATCCAATATCAAAGGAAATGATAGC-3' (SEQ ID NO:43) CF128 5'-GCTATCATTTCCTTTGATATTGGATACGTATCATACCCTAGAAGTATTACG-3' (SEQ ID NO:44)

21. Please replace Table 7 on page 90 with the following table (underlining in sequences are in original):

Primer	Description	Sequence
DS299	5' PDII	5'- CGTAGCGGCCGCCTGAAAGGGGTTGACCGTCCGT
(SEQ ID NO: 45)	primer, 38mer	CGGC -3'

Synnestvedt & Lechner LLP In Re: Application of D. Sleep, et al U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 8

Primer	Description	Sequence
DS300	5' PDII	5'-CGTAAAGCTTCGCCGCCCGACAGGGTAACATATTAT
(SEQ ID NO: 46)	primer, 40mer	CAC -3'
DS301	3' <i>PDI1</i>	5'-CGTA <u>AAGCTT</u> GACCACGTAGTAATAATAAGTGCAT
(SEQ ID NO: 47)	primer, 38mer	GGC-3'
DS302	3' <i>PDI1</i>	5'-CGTACTGCAGATTGGATAGTGATTAGAGTGTATAGTCC
(SEQ ID NO: 48)	primer, 41mer	CGG-3'
DS303	18mer	5'-GGAGCGACAAACCTTTCG-3'
(SEQ ID NO: 49)		
DS304	20mer	5'-ACCGTAATAAAAGATGGCTG-3'
(SEQ ID NO: 50)		
DS305	24mer	5'-CATCTTGTGTGAGTATGGTCGG-3'
(SEQ ID NO: 51)		
DS306	14mer	5'-CCCAGGATAATTTTCAGG-3'
(SEQ ID NO: 52)		

22. Please replace Table 8 on page 92 with the following table:

Primer	Description	Sequence	
DS230	TRP1 5' UTR	5'-TAGCGAATTC AATCAGTAAAAATCAACGG-3'	
(SEQ ID NO:53)			
DS231	TRP1 5' UTR	5'-GTCAAAGCTTCAAAAAAAGA AAAGCTCCGG-3'	
(SEQ ID NO:54)			
DS232	TRP1 3' UTR	5'-TAGCGGATCCGAATTCGGCGGTTGTTTGCAAGACC	
(SEQ ID NO:55)		GAG-3'	
DS233	<i>TRP1</i> 3' UTR	5'-GTCAAAGCTTTAAAGATAATGCTAAATCATTTGG-3'	
(SEQ ID NO:56)			

Synnestvedt & Lechner Llp In Re: Application of D. Sleep, et al U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 9

DS234	TRP1	5'-TGACAAGCTTTCGGTCGAAAAAAGAAAAGG AG
(SEQ ID NO:57)		AGG-3'
DS235	TRP1	5'-TGACAAGCTTGATCTTTATGCTTGCTTTTC-3'
(SEQ ID NO:58)		
DS236	TRP1	5'-AATAGTTCAGGCACTCCG-3'
(SEQ ID NO:59)		
DS237	TRP1	5'-TGGAAGGCAAGAGACC-3'
(SEQ ID NO:60)		
DS238	TRP1	5'-TAAAATGTAAGCTCTCGG-3'
(SEQ ID NO:61)		
DS239	TRP1	5'-CCAACCAAGTATTTCGG-3'
(SEQ ID NO:62)		
CED005	∆TRP1	5'-GAGCTGACAGGGAAATGGTC-3'
(SEQ ID NO:63)		
CED006	∆TRP1	5'-TACGAGGATACGGAGAGAGG-3'
(SEQ ID NO:64)		

23. Please replace Table 11 on page 99 with the following table:

Primer	Sequence
DS248	5'-GTCAGAATTCGAGCTCTACGTATTAATTAAGGCCGGCCAGGCCCGGGCTAGT
(SEQ ID NO: 65)	CTCTTTTTCCAATTTGCCACCGTGTAGCATTTTGTTGT-3'
DS249	5'-GTCAGGATCCTACGTACCCGGGGATATCATTATCATCTTTGTCGTGGTCATCT
(SEQ ID NO: 66)	TGTGTG-3'
DS250	5'-GTCAGGATCCTACGTACCCGGGTAAGGCGTTCGTGCAGTGTGACGAATAT
(SEQ ID NO: 67)	AGCG-3'
DS251	5'-GTCAGAATTCGAGCTCTACGTATTAATTAAGGCCGGCCCAGGCCCGGGCCCGT

Synnestvedt & Lechner Llp In Re: Application of D. Sleep, et al U.S. Application No. 10/584,486

Attorney Docket No. P31,747 USA September 20, 2007

Page: 10

(SEQ ID NO: 68)	ATGGACATACATATATATATATATATATATATTTTTTTTT
DS252	5'-GTCAGAATTCGAGCTCTACGTATTAATTAAGGCCGGCCCAGGCCCGGGCTTGTTG
(SEQ ID NO: 69)	CAAGCAGCATGTCTAATTGGTAATTTTAAAGCTGCC-3'
sDS267	5'-GTCAGAATTCGAGCTCTACGTATTAATTAAGGCCGGCCCAGGCCCGGGCCCGTA
(SEQ ID NO: 70)	TGGACATACATATATATATATATATATATATATATTTTTGTTACGCG-3'

24. Please replace Table 12 on page 100 with the following table:

<u>Primer</u>	Sequence
DS253	5'-CCTCCCTGCTGCTCGCC-3'
(SEQ ID NO: 71)	
DS254	5'-CTGTAAGAACATGGCTCC-3'
(SEQ ID NO: 72)	
DS255	5'-CTCGATCGATTACGAGGG-3'
(SEQ ID NO: 73	
DS256	5'-AAGAAAGCCGATATCGC-3'
(SEQ ID NO: 74)	
DS257	5'-CAACTCTCTGAAGAGGCG-3'
(SEQ ID NO: 75)	
DS258	5'-CAACGCCACATCCGACG-3'
(SEQ ID NO: 76)	
DS259	5'-GTAATTCTGATCACTTTGG-3'
(SEQ ID NO: 77)	
DS260	5'-GCACTTATTATTACTACGTGG-3'
(SEQ ID NO: 78)	
DS261	5'-GTTTTCCTTGATGAAGTCG-3'
(SEQ ID NO: 79)	

Synnestvedt & Lechner LLP In Re: Application of D. Sleep, et al

Attorney Docket No. P31,747 USA U.S. Application No. 10/584,486 September 20, 2007

, -		_	
Page	:	1	1

DS262	5'-GTGACCACACCATGGGGC-3'
(SEQ ID NO: 80)	
DS263	5'-GTTGCCGGCGTGTCTGCC-3'
(SEQ ID NO: 81)	
DS264	5'-TTGAAATCATCGTCTGCG-3'
(SEQ ID NO: 82)	
DS265	5'-CGGCAGTTCTAGGTCCC-3'
(SEQ ID NO: 83)	
DS266	5'-CCACAGCCTCTTGTTGGG-3'
(SEQ ID NO: 84)	
M13/pUC Primer (-40)	5'-GTTTTCCCAGTCACGAC-3'
(SEQ ID NO: 85)	

25. Please insert the enclosed Sequence Listing after the Abstract and before the Figures in accordance with 37 C.F.R. §1.77(b).